ASH 2019 | Cost-effectiveness of 12-month VenG for CLL

Matthew Davids

Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, discusses a study estimating the cost-effectiveness of a 12-month fixed duration of venetoclax in combination with obinutuzumab (VenG) for the first-line treatment of chronic lymphocytic leukemia (CLL) in the United States. A 12-month fixed-duration treatment with VenG appears to be a cost-effective standard therapy for CLL patients. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter